GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Traws Pharma Inc (STU:0T20) » Definitions » Float Percentage Of Total Shares Outstanding

Traws Pharma (STU:0T20) Float Percentage Of Total Shares Outstanding : 59.90% (As of Apr. 15, 2025)


View and export this data going back to 2013. Start your Free Trial

What is Traws Pharma Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Traws Pharma's float shares is 3.01 Mil. Traws Pharma's total shares outstanding is 5.03 Mil. Traws Pharma's float percentage of total shares outstanding is 59.90%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Traws Pharma's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Traws Pharma's Institutional Ownership is 1.79%.


Traws Pharma Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Traws Pharma's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=3.01/5.03
=59.90%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Traws Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Traws Pharma Inc (STU:0T20) » Definitions » Float Percentage Of Total Shares Outstanding
Traded in Other Exchanges
Address
12 Penns Trail, Newtown, PA, USA, 18940
Traws Pharma Inc is a biopharmaceutical company focused on developing antivirals for influenza, COVID and other respiratory infections and narazaciclib.

Traws Pharma Headlines

No Headlines